296 related articles for article (PubMed ID: 26874696)
41. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.
Gomez-Hernandez K; Ezzat S; Asa SL; Mete Ö
Turk Patoloji Derg; 2015; 31 Suppl 1():4-17. PubMed ID: 26177314
[TBL] [Abstract][Full Text] [Related]
42. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification.
Micko AS; Wöhrer A; Wolfsberger S; Knosp E
J Neurosurg; 2015 Apr; 122(4):803-11. PubMed ID: 25658782
[TBL] [Abstract][Full Text] [Related]
43. Pituitary adenomas.
McNicol AM
Histopathology; 1987 Oct; 11(10):995-1011. PubMed ID: 3332648
[TBL] [Abstract][Full Text] [Related]
44. Pathology of pituitary tumors.
Kovacs K; Horvath E
Endocrinol Metab Clin North Am; 1987 Sep; 16(3):529-51. PubMed ID: 3319594
[TBL] [Abstract][Full Text] [Related]
45. [Clinical and genetic characterization of FIPA (familial isolated pituitary adenomas)].
Beckers A; Apetrii P; Daly A; Tichomirova M; Vanbellingen JF; Georges M; Bours V
Rev Med Liege; 2009; 64 Spec No():15-9. PubMed ID: 20085010
[TBL] [Abstract][Full Text] [Related]
46. [Classification, pathology and molecular biology of pituitary adenoma].
Tapar K; Kovach K; Khorvat E
Arkh Patol; 1997; 59(3):7-17. PubMed ID: 9290033
[TBL] [Abstract][Full Text] [Related]
47. Metabolic profiling reveals distinct metabolic alterations in different subtypes of pituitary adenomas and confers therapeutic targets.
Feng J; Gao H; Zhang Q; Zhou Y; Li C; Zhao S; Hong L; Yang J; Hao S; Hong W; Zhuang Z; Xu G; Zhang Y
J Transl Med; 2019 Aug; 17(1):291. PubMed ID: 31455412
[TBL] [Abstract][Full Text] [Related]
48. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
49. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
50. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.
Horvath A; Stratakis CA
Rev Endocr Metab Disord; 2008 Mar; 9(1):1-11. PubMed ID: 18200440
[TBL] [Abstract][Full Text] [Related]
51. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex).
Pack SD; Kirschner LS; Pak E; Zhuang Z; Carney JA; Stratakis CA
J Clin Endocrinol Metab; 2000 Oct; 85(10):3860-5. PubMed ID: 11061550
[TBL] [Abstract][Full Text] [Related]
52. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.
Leontiou CA; Gueorguiev M; van der Spuy J; Quinton R; Lolli F; Hassan S; Chahal HS; Igreja SC; Jordan S; Rowe J; Stolbrink M; Christian HC; Wray J; Bishop-Bailey D; Berney DM; Wass JA; Popovic V; Ribeiro-Oliveira A; Gadelha MR; Monson JP; Akker SA; Davis JR; Clayton RN; Yoshimoto K; Iwata T; Matsuno A; Eguchi K; Musat M; Flanagan D; Peters G; Bolger GB; Chapple JP; Frohman LA; Grossman AB; Korbonits M
J Clin Endocrinol Metab; 2008 Jun; 93(6):2390-401. PubMed ID: 18381572
[TBL] [Abstract][Full Text] [Related]
53. [Pathology of functioning pituitary adenomas with emphasis on the immunohistochemical classification (author's transl)].
Teramoto A
No To Shinkei; 1981 May; 33(5):479-88. PubMed ID: 6266441
[No Abstract] [Full Text] [Related]
54. AIP gene and familial isolated pituitary adenomas.
Ozfirat Z; Korbonits M
Mol Cell Endocrinol; 2010 Sep; 326(1-2):71-9. PubMed ID: 20457215
[TBL] [Abstract][Full Text] [Related]
55. Computational analysis identifies invasion-associated genes in pituitary adenomas.
Cao C; Wang W; Ma C; Jiang P
Mol Med Rep; 2015 Aug; 12(2):1977-82. PubMed ID: 25824863
[TBL] [Abstract][Full Text] [Related]
56. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.
Gong J; Zhao Y; Abdel-Fattah R; Amos S; Xiao A; Lopes MB; Hussaini IM; Laws ER
Pituitary; 2008; 11(1):37-48. PubMed ID: 17768685
[TBL] [Abstract][Full Text] [Related]
57. Clinical and cytofunctional classification of pituitary adenomas: proposal of a new classification.
Sanno N; Teramoto A; Osamura RY
Acta Neurochir (Wien); 1996; 138(10):1186-92. PubMed ID: 8955438
[TBL] [Abstract][Full Text] [Related]
58. The classification and molecular biology of pituitary adenomas.
Thapar K; Kovacs K; Laws ER
Adv Tech Stand Neurosurg; 1995; 22():3-53. PubMed ID: 7495421
[No Abstract] [Full Text] [Related]
59. Expression of neuro D1 in human normal pituitaries and pituitary adenomas.
Oyama K; Sanno N; Teramoto A; Osamura RY
Mod Pathol; 2001 Sep; 14(9):892-9. PubMed ID: 11557786
[TBL] [Abstract][Full Text] [Related]
60. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas.
Chen Y; Chuan HL; Yu SY; Li CZ; Wu ZB; Li GL; Zhang YZ
World Neurosurg; 2017 Apr; 100():514-521. PubMed ID: 28093347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
